Literature DB >> 9817705

Aerosolized soluble nitric oxide donor improves oxygenation and pulmonary hypertension in acute lung injury.

B R Jacobs1, R J Brilli, E T Ballard, D J Passerini, D J Smith.   

Abstract

Acute respiratory distress syndrome (ARDS) is a major cause of morbidity and mortality in critically ill patients. The associated ventilation/perfusion mismatch and pulmonary hypertension are amenable to treatment with inhaled nitric oxide (NO) gas. Compounds formed by reacting NO with various nucleophiles (NONOates) release NO spontaneously and induce vasodilation. Intratracheally administered NONOates result in selective reduction in pulmonary hypertension. We hypothesized that a nebulized NONOate would improve oxygenation and reduce pulmonary vascular resistance in oleic acid-induced acute lung injury and pulmonary hypertension. Pigs underwent catheterization of the pulmonary artery, left atrium, and right atrium, and a flow probe was positioned around the pulmonary artery. Acute lung injury and pulmonary hypertension were induced with intravenous oleic acid. Animals were randomly assigned to receive either nebulized saline or the NONOate 2-(dimethylamino)ethylputreanine/NO (DMAEP/NO). Hemodynamic, gas exchange, pulmonary function, methemoglobin, and nitrite/nitrate measurements were obtained for 60 min. Animals in the DMAEP/NO group had improvement in PaO2 as compared with control animals (from 139 +/- 19 mm Hg to 180 +/- 19 mm Hg in the DMAEP/NO group [n = 6]; and from 144 +/- 6 mm Hg to 150 +/- 9 mm Hg in the saline group [n = 6], p < 0.05). After aerosol treatment, animals in the DMAEP/NO group had a greater reduction in pulmonary vascular resistance index (PVRI) than did control animals (from 81 +/- 17 dyne. s/cm5/kg to 34 +/- 8 dyne. s/cm5/kg; and from 104 +/- 16 dyne. s/cm5/kg to 64 +/- 11 dyne. sec/cm5/ kg in the saline group at 60 min, p < 0.05). There were no differences between the groups in systemic vascular resistance index (SVRI), cardiac index (CI), methemoglobin, nitrite/nitrate, or lung pathology scores. We conclude that DMAEP/NO improves oxygenation and has selective pulmonary vasodilating properties without causing significant systemic toxicity in this porcine model of acute lung injury.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9817705     DOI: 10.1164/ajrccm.158.5.9802114

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  6 in total

1.  Effect of chronic sodium nitrite therapy on monocrotaline-induced pulmonary hypertension.

Authors:  Edward A Pankey; Adeleke M Badejo; David B Casey; George F Lasker; Russel A Riehl; Subramanyam N Murthy; Bobby D Nossaman; Philip J Kadowitz
Journal:  Nitric Oxide       Date:  2012-03-14       Impact factor: 4.427

Review 2.  Newer approaches and novel drugs for inhalational therapy for pulmonary arterial hypertension.

Authors:  Ali Keshavarz; Hossam Kadry; Ahmed Alobaida; Fakhrul Ahsan
Journal:  Expert Opin Drug Deliv       Date:  2020-02-19       Impact factor: 6.648

Review 3.  Inhaled nitric oxide: role in the pathophysiology of cardio-cerebrovascular and respiratory diseases.

Authors:  Lorenzo Berra; Emanuele Rezoagli; Davide Signori; Aurora Magliocca; Kei Hayashida; Jan A Graw; Rajeev Malhotra; Giacomo Bellani
Journal:  Intensive Care Med Exp       Date:  2022-06-27

4.  Diazeniumdiolate reactivity in model membrane systems.

Authors:  Bach T Dinh; Stacy E Price; Amr Majul; Mazen El-Hajj; Victor Morozov; Joseph A Hrabie; Keith M Davies
Journal:  Nitric Oxide       Date:  2007-11-21       Impact factor: 4.427

5.  In vivo pharmacological activity and biodistribution of S-nitrosophytochelatins after intravenous and intranasal administration in mice.

Authors:  Lamia Heikal; Anna Starr; Gary P Martin; Manasi Nandi; Lea Ann Dailey
Journal:  Nitric Oxide       Date:  2016-06-24       Impact factor: 4.427

6.  Electrical impedance tomography (EIT) for quantification of pulmonary edema in acute lung injury.

Authors:  Constantin J C Trepte; Charles R Phillips; Josep Solà; Andy Adler; Sebastian A Haas; Michael Rapin; Stephan H Böhm; Daniel A Reuter
Journal:  Crit Care       Date:  2016-01-22       Impact factor: 9.097

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.